Trial · NCT01196416
Outcomes11
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
1 to 11 of 11
Download this page as JSON| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Overall Objective Response | From the time measurement criteria are met for CR or PR until the first date that recurrent or progressive disease is objectively documented, assessed up to 2 years | Participants | COUNT_OF_PARTICIPANTS | |
| PRIMARY | Maximum-tolerated Dose for Cisplatin, Vinblastine and TMZ | 21 days | mg/m2 | NUMBER | |
| PRIMARY | Overall Survival (Phase II) | Up to 2 years | participants | NUMBER | |
| PRIMARY | Maximum Tolerated Dose for RO4929097 | 21 days | mg/day | NUMBER | |
| SECONDARY | Participants' Change in Protein Levels | Baseline up to 2 weeks | Participants | COUNT_OF_PARTICIPANTS | |
| SECONDARY | Cycle 1 AUC/Pharmacokinetics of Gamma-secretase Inhibitor RO4929097 in Combination With Temozolomide (Phase IB) | Days 4 and 5 | hr·ng/mL | MEAN | |
| SECONDARY | Cycle 1 C Max/Pharmacokinetics of Gamma-secretase Inhibitor RO4929097 in Combination With Temozolomide (Phase IB) | At Cycle 1 | ng/mL | MEAN | |
| SECONDARY | Cycle 1 Mean Day 2 Trough/Pharmacokinetics of Gamma-secretase Inhibitor RO4929097 in Combination With Temozolomide (Phase IB) | At Day 2 of Cycle 1 | ng/mL | MEAN | |
| SECONDARY | Number of Participants With Presence or Absence of Markers of Notch Signalling Pathway Inhibition in Patient Tumors (Phase Ib) | 2 weeks | Participants | COUNT_OF_PARTICIPANTS | |
| SECONDARY | Progression-free Survival (Phase II) | Time from start of treatment to time of progression or death, whichever occurs first, assessed up to 2 years | months | MEDIAN | |
| SECONDARY | Participants Evaluated for Toxicity | Up to 30 days post-treatment | Participants | COUNT_OF_PARTICIPANTS |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01196416/outcomes